Compare Stocks → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:IMRNNASDAQ:NVUSNASDAQ:TRILNASDAQ:TRPX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMRNImmuron$2.45+1.7%$5.04$1.92▼$28.99$13.97M1.4325,230 shs9,601 shsNVUSNovus Therapeutics$1.99+26.8%$13.23$4.50▼$27.32$2.86M2.0778,851 shs400,123 shsTRILTrillium Therapeutics$18.44$18.12$5.80▼$20.96$1.94B2.081.87 million shs8 shsTRPXTherapix Biosciences$0.10$0.23$0.25▼$4.69$351KN/A1.59 million shs95,212 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMRNImmuron+1.66%-14.08%-7.89%+36.11%+23.74%NVUSNovus Therapeutics0.00%-5.42%-3.09%-5.99%-38.43%TRILTrillium Therapeutics0.00%0.00%0.00%0.00%0.00%TRPXTherapix Biosciences0.00%0.00%0.00%0.00%0.00%New crypto project uncovers 2,050% in 65 days (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMRNImmuronN/AN/AN/AN/AN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATRPXTherapix BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMRNImmuronN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/ATRPXTherapix BiosciencesN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMRNImmuron$1.22M11.45N/AN/A$2.32 per share1.06NVUSNovus TherapeuticsN/AN/AN/AN/A$13.13 per shareN/ATRILTrillium Therapeutics$150K12,907.39N/AN/A$2.56 per share7.20TRPXTherapix BiosciencesN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMRNImmuron-$2.55MN/A0.00∞N/AN/AN/AN/AN/ANVUSNovus Therapeutics-$16.01M-$21.58N/AN/AN/AN/A-133.49%-30.52%N/ATRILTrillium Therapeutics-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/ATRPXTherapix Biosciences-$4.79MN/A0.00∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMRNImmuronN/AN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/ATRPXTherapix BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMRNImmuronN/A8.527.79NVUSNovus TherapeuticsN/A18.7818.78TRILTrillium TherapeuticsN/A19.8219.82TRPXTherapix BiosciencesN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMRNImmuron0.12%NVUSNovus TherapeuticsN/ATRILTrillium Therapeutics87.15%TRPXTherapix Biosciences14.32%Insider OwnershipCompanyInsider OwnershipIMRNImmuron7.01%NVUSNovus Therapeutics2.20%TRILTrillium Therapeutics9.10%TRPXTherapix BiosciencesN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIMRNImmuronN/A5.70 million5.30 millionNot OptionableNVUSNovus Therapeutics71.44 millionN/ANot OptionableTRILTrillium Therapeutics33105.00 million95.44 millionOptionableTRPXTherapix Biosciences93.51 millionN/ANot OptionableTRIL, NVUS, IMRN, and TRPX HeadlinesSourceHeadlineAnixa Biosciences Stock (NASDAQ:ANIX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - December 12 at 5:48 AMSagimet Biosciences Inc (SGMT)investing.com - August 23 at 7:29 AMPBIO Pressure BioSciences, Inc.seekingalpha.com - August 1 at 3:24 PMCannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOsthestreet.com - January 19 at 7:59 PMNew MarketBeat Followers Over TimeCompany DescriptionsImmuronNASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Novus TherapeuticsNASDAQ:NVUSNovus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.Trillium TherapeuticsNASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.Therapix BiosciencesNASDAQ:TRPX Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.